SOPHiA GENETICS
SOPH
30 hedge funds and large institutions have $331M invested in SOPHiA GENETICS in 2021 Q3 according to their latest regulatory filings, with 30 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
29.42% more ownership
Funds ownership: 0% → 29.42% (+29%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Generation Investment Management
London,
United Kingdom
|
+$119M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$41.5M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$35.6M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$33.1M |
| 5 |
GE
General Electric
Evendale,
Ohio
|
+$19.5M |
Top Sellers
SOPH Hedge Fund Activity: Q3 2021 in Review
30 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in SOPHiA GENETICS (SOPH) for Q3 2021, worth a combined $331M.
Buyers outnumbered sellers: 30 funds opened new SOPH positions and 0 closed out — a net gain of 30 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Generation Investment Management, opening a new position worth an estimated $119M.
- 30 institutional investors held SOPHiA GENETICS (SOPH) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $331M of SOPHiA GENETICS stock for Q3 2021.
- 30 funds opened new SOPHiA GENETICS positions in Q3 2021 and 0 closed out, a net change of +30 holders.
- The largest SOPHiA GENETICS buyer in Q3 2021 was Generation Investment Management, an estimated $119M added.
Based on aggregated 13F filings for Q3 2021.